QF0159 Marketing Release Record

Novocastra BL-CAM (CD22)
Clone FPC1
1 mL, 0.1 mL lyophilized NCL-CD22-2 P (HIER)
See also CD22 (BL-CAM) on page 37.
Novocastra Blood Coagulation Factor
XIIIa (Factor XIIIa)
Clone E980.1
1 mL, 0.1 mL lyophilized NCL-FXIIIa P (HIER)
7 mL BOND ready-to-use PA0449 P (HIER)
See also Factor XIIIa (Blood Coagulation Factor XIIIa) on page 63.
Novocastra Bone Morphogenetic
Protein 4
Clone 3H2
1 mL lyophilized NCL-BMP4 PW
RUO*
Bone morphogenetic protein 4 (BMP4) is one of nine structurally related
BMPs belonging to the transforming growth factor beta (TGF-beta) superfamily
of secreted proteins. Mature BMP4 is a dimer that binds to a
multimeric transmembrane receptor with serine/threonine kinase activity.
Although BMP4 was discovered because it stimulates bone formation in
adult mammals, it has important roles as a signalling molecule in embryonic
tissues including the developing central and peripheral nervous system,
musculature and skeleton. It also participates in a signalling pathway found
in insects and worms. BMP4 is implicated in fibrodysplasia ossificans
progressive. It is reported to be uniquely overexpressed in lymphoblastoid
cells and preosseous fibroproliferative lesions. BMPs 1 to 6 are also
reported to be expressed in prostatic adenocarcinomas with BMPs 1 to 5
also expressed in both benign and prostatic hyperplasia and ocular
melanoma.
Western blot: detection of bone morphogenetic protein 4 (21 kD) using NCL-BMP4. Lane A,
molecular weight markers. Lane B, Saos-2 cell line immunoblotted with NCL-BMP4.
IVD
RUO*
IVD
Novocastra Bromodeoxyuridine
Clone 85-2C8
1 mL lyophilized NCL-BrdU FP
5-Bromodeoxyuridine (BrdU) is an analogue of thymidine. BrdU can be
introduced to *live proliferating cells which in turn incorporate BrdU into the
DNA during S phase, prior to cell division. Immunocytochemical staining for
BrdU is an accurate method for measuring cell proliferation and detects
nucleated cells from different animal species which have incorporated BrdU
in place of thymidine into their DNA. The detection of BrdU incorporation
can be used to determine the proliferative response of cells to mitogenic
stimuli and to monitor the effects of various treatments on tumors.
*Protocol included with product indicates a requirement to incubate fresh
tissue fragments with bromodeoxyuridine before fixation and embedding
followed by sectioning and finally antibody incubation NCL-BrdU via
immunohistochemistry.
Normal human colon biopsy incubated with BrdU and stained using NCL-BrdU. Note intense
nuclear staining of a small proportion of crypt epithelial cells. Paraffin section.
Novocastra CA19-9 (Sialyl Lewis a )
Clone C241:5:1:4
1 mL lyophilized NCL-CA19-9 F P (HIER)
1 mL liquid NCL-L-CA19-9 F P (HIER) RUO*
7 mL BOND ready-to-use PA0424 P (HIER)
Antigen Background
CA19-9 is an epitope on the sialylated Lewis a carbohydrate structure.
Sialylated Lewis a plays a role in cell adhesion by acting as a functional ligand
for the inducible adhesion molecule E-selectin. CA19-9 and CA50 (carcinoma
associated mucin antigen) are useful serum markers in the diagnosis and
follow up of gastrointestinal and pancreatic cancers. In carcinoma of the
pancreas, it is reported that the immunohistochemical expression of both
CA19-9 and CA50 correlates with tumor differentiation where the strongest
staining is observed in well differentiated tumors. These two markers are also
reported in a number of benign lesions such as chronic pancreatitis.
Product Specific Information
Clone C241:5:1:4 reacts specifically with Sialyl Lewis a - containing glycolipids,
showing no crossreaction with Lewis a , Lewis b , or other structurally related
molecules. The epitope recognized by NCL-L-CA19-9 is designated CA19-9
and is similar to CA50 (carcinoma associated mucin antigen).
F Frozen I Immunofluorescence E Electron microscopy
P Paraffin C Flow cytometry O Other applications
W Western blotting
IVD
RUO*
IVD
/27
Primary Antibodies